Mental healthcare psychedelics company Numinus Wellness (OTCQX: NUMIF) shared its financial results for the three months ended November 30, 2022.

"During the first quarter of fiscal 2023, we successfully implemented several initiatives to increase access to psychedelic and ketamine-assisted therapy. We believe expanded access will not only serve to elevate Numinus' leadership position within the psychedelic industry but strongly supports the overall advancement of psychedelic medicine for the treatment of mental health,” stated founder and CEO Payton Nyquvest.

See also: Numinus CEO Payton Nyquvest Believes MDMA "Most Likely" To Be Approved At The End Of 2023

Financials for 2023’s first quarter showed revenue growth of 618% YoY, to $4.2 (CA$5.7) …

Full story available on Benzinga.com